Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Expert Review of Clinical Pharmacology
|
October 28, 2017
Pharmacology and pharmacokinetics of imatinib in pediatric patients
Meinolf Suttorp, Martin Bornhäuser, Markus Metzler, et al.
Annals of Hematology
|
May 23, 2009
Imatinib in breast milk
Roland Kronenberger, Eberhard Schleyer, Martin Bornhäuser, et al.
Anticancer Research
|
January 18, 2003
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity
Wolfgang Kern, Jan Braess, Marion Kotschofsky, et al.
Onkologie
|
September 22, 2011
Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study
Annekathrin Roth, Eberhard Schleyer, Konrad Schoppmeyer, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 29, 2004
Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis
Andreas Jenke, Ulf Renner, Ulrich S Schuler, et al.
Journal of Pharmacological and Toxicological Methods
|
March 31, 2007
A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography
Thomas Illmer, Hans-M Thiede, Christian Thiede, et al.
Cancer
|
March 23, 2007
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial
Salah-Eddin Al-Batran, Akin Atmaca, Eberhard Schleyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2005
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib
Martin Bornhäuser, Stefan Pursche, Malte Bonin, et al.
Cancer Chemotherapy and Pharmacology
|
June 21, 2007
Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas
Frank P Kroschinsky, Kai Friedrichsen, Juliane Mueller, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2003
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment
Alexander Kiani, Claus-Henning Köhne, Thorsten Franz, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Expert Review of Clinical Pharmacology
|
October 28, 2017
Pharmacology and pharmacokinetics of imatinib in pediatric patients
Meinolf Suttorp, Martin Bornhäuser, Markus Metzler, et al.
Annals of Hematology
|
May 23, 2009
Imatinib in breast milk
Roland Kronenberger, Eberhard Schleyer, Martin Bornhäuser, et al.
Anticancer Research
|
January 18, 2003
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity
Wolfgang Kern, Jan Braess, Marion Kotschofsky, et al.
Onkologie
|
September 22, 2011
Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study
Annekathrin Roth, Eberhard Schleyer, Konrad Schoppmeyer, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 29, 2004
Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis
Andreas Jenke, Ulf Renner, Ulrich S Schuler, et al.
Journal of Pharmacological and Toxicological Methods
|
March 31, 2007
A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography
Thomas Illmer, Hans-M Thiede, Christian Thiede, et al.
Cancer
|
March 23, 2007
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial
Salah-Eddin Al-Batran, Akin Atmaca, Eberhard Schleyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2005
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib
Martin Bornhäuser, Stefan Pursche, Malte Bonin, et al.
Cancer Chemotherapy and Pharmacology
|
June 21, 2007
Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas
Frank P Kroschinsky, Kai Friedrichsen, Juliane Mueller, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2003
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment
Alexander Kiani, Claus-Henning Köhne, Thorsten Franz, et al.
Page
of 3